Wells Fargo & Company Adial Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$0.21 - $0.37 $153 - $270	-732 Reduced 79.65%	187 $0
Q1 2023 May 12, 2023	BUY	$0.24 - $0.56 $0 - $1	3 Added 0.33%	919 $0
Q4 2022 Feb 13, 2023	SELL	$0.2 - $9.25 $17 - $823	-89 Reduced 8.86%	916 $0
Q3 2022 Nov 14, 2022	BUY	$0.03 - $46.0 $0 - $414	9 Added 0.9%	1,005 $0
Q2 2022 Aug 12, 2022	BUY	$28.0 - $53.25 $784 - $1,491	28 Added 2.89%	996 $1,000
Q1 2022 May 16, 2022	BUY	$45.0 - $69.0 $4,635 - $7,107	103 Added 11.91%	968 $2,000
Q3 2021 Nov 15, 2021	BUY	$57.75 - $116.75 $2,425 - $4,903	42 Added 5.1%	865 $3,000
Q2 2021 Aug 16, 2021	BUY	$50.5 - $78.25 $757 - $1,173	15 Added 1.86%	823 $2,000
Q1 2021 May 13, 2021	BUY	$43.25 - $79.75 $129 - $239	3 Added 0.37%	808 $2,000
Q4 2020 Feb 09, 2021	BUY	$42.25 - $58.25 $253 - $349	6 Added 0.75%	805 $1,000
Q3 2020 Nov 05, 2020	BUY	$30.25 - $75.75 $242 - $606	8 Added 1.01%	799 $2,000
Q1 2020 May 14, 2020	BUY	$26.25 - $61.75 $20,763 - $48,844	791 New	791 $1,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $26.6M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.